CoChat
Sign Up
Cited by 67

The DOI matches its Crossref record.

High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)

Cheung, Leanna, Flemming, Claudia L., Watt, Fujiko, Masada, Nanako, Yu, Denise M.T., Huynh, Tony, Conseil, Gwenaëlle, Tivnan, Amanda, Polinsky, Alexander, Gudkov, Andrei V., Munoz, Marcia A., Vishvanath, Anasuya, Cooper, Dermot M.F., Henderson, Michelle J., Cole, Susan P.C., Fletcher, Jamie I., Haber, Michelle, Norris, Murray D.·2014·Biochemical Pharmacology
DOI 10.1016/j.bcp.2014.05.023
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2014.05.023

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 51

  1. Keppler, 2011, Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy, Handb Exp Pharmacol, 299, 10.1007/978-3-642-14541-4_8 · DOI
  2. Russel, 2008, Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules, Trends Pharmacol Sci, 29, 200, 10.1016/j.tips.2008.01.006 · DOI · Paper page
  3. Slot, 2011, Mammalian multidrug-resistance proteins (MRPs), Essays Biochem, 50, 179, 10.1042/bse0500179 · DOI
  4. Fukuda, 2013, Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity, Mol Pharmacol, 84, 361, 10.1124/mol.113.086967 · DOI
  5. Belinsky, 2007, Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage, Cancer Res, 67, 262, 10.1158/0008-5472.CAN-06-2680 · DOI
  6. Leggas, 2004, Mrp4 confers resistance to topotecan and protects the brain from chemotherapy, Mol Cell Biol, 24, 7612, 10.1128/MCB.24.17.7612-7621.2004 · DOI
  7. Furmanski, 2013, Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib, Clin Cancer Res, 19, 4359, 10.1158/1078-0432.CCR-13-0980 · DOI
  8. Hara, 2011, Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice, J Clin Invest, 121, 2888, 10.1172/JCI45023 · DOI
  9. Jedlitschky, 2012, Transporters in human platelets: physiologic function and impact for pharmacotherapy, Blood, 119, 3394, 10.1182/blood-2011-09-336933 · DOI
  10. Mattiello, 2011, Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting, J Am Coll Cardiol, 58, 752, 10.1016/j.jacc.2011.03.049 · DOI
  11. Norris, 2005, Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro, Mol Cancer Ther, 4, 547, 10.1158/1535-7163.MCT-04-0161 · DOI
  12. Henderson, 2011, ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux, J Nat Cancer Inst, 103, 1236, 10.1093/jnci/djr256 · DOI
  13. Copsel, 2011, Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation, J Biol Chem, 286, 6979, 10.1074/jbc.M110.166868 · DOI
  14. Sinha, 2013, Multi-drug resistance protein 4 (MRP4)-mediated regulation of fibroblast cell migration reflects a dichotomous role of intracellular cyclic nucleotides, J Biol Chem, 288, 3786, 10.1074/jbc.M112.435925 · DOI
  15. Lin, 2008, Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response, Mol Pharmacol, 73, 243, 10.1124/mol.107.039594 · DOI
  16. Reid, 2003, Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5, Mol Pharmacol, 63, 1094, 10.1124/mol.63.5.1094 · DOI
  17. Reid, 2003, The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs, Proc Nat Acad Sci USA, 100, 9244, 10.1073/pnas.1033060100 · DOI · Paper page
  18. Cole, 2014, Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future, Annu Rev Pharmacol Toxicol, 54, 95, 10.1146/annurev-pharmtox-011613-135959 · DOI
  19. Leier, 1994, The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates, J Biol Chem, 269, 27807, 10.1016/S0021-9258(18)46856-1 · DOI
  20. Jones, 1989, Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist, Can J Physiol Pharmacol, 67, 17, 10.1139/y89-004 · DOI
  21. Xie, 2011, Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP, Mol Pharmacol, 80, 281, 10.1124/mol.111.071134 · DOI
  22. Wielinga, 2002, Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells, Mol Pharmacol, 62, 1321, 10.1124/mol.62.6.1321 · DOI
  23. Wijnholds, 2000, Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs, Proc Nat Acad Sci USA, 97, 7476, 10.1073/pnas.120159197 · DOI
  24. Evers, 2000, Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport, Br J Cancer, 83, 366, 10.1054/bjoc.2000.1260 · DOI
  25. Kool, 1999, MRP3, an organic anion transporter able to transport anti-cancer drugs, Proc Nat Acad Sci USA, 96, 6914, 10.1073/pnas.96.12.6914 · DOI
  26. Robey, 2003, Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity, Br J Cancer, 89, 1971, 10.1038/sj.bjc.6601370 · DOI
  27. Schneider, 1994, Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance, Cancer Res, 54, 152
  28. Ciccarone, 1989, Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages, Cancer Res, 49, 219
  29. Kinsella, 1996, Episomal vectors rapidly and stably produce high-titer recombinant retrovirus, Hum Gene Ther, 7, 1405, 10.1089/hum.1996.7.12-1405 · DOI
  30. Rabindran, 2000, Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein, Cancer Res, 60, 47
  31. Burkhart, 2009, Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma, Cancer Res, 69, 6573, 10.1158/0008-5472.CAN-09-1075 · DOI
  32. Strouse, 2013, A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry, J Biomol Screen, 18, 26, 10.1177/1087057112456875 · DOI
  33. Wachten, 2010, Distinct pools of cAMP centre on different isoforms of adenylyl cyclase in pituitary-derived GH3B6 cells, J Cell Sci, 123, 95, 10.1242/jcs.058594 · DOI
  34. Myette, 2013, Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4, Drug Metab Dispos, 41, 1231, 10.1124/dmd.112.050831 · DOI
  35. Loe, 1996, Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport, J Biol Chem, 271, 9675, 10.1074/jbc.271.16.9675 · DOI
  36. Romanov, 2008, Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors, Nat Methods, 5, 253, 10.1038/nmeth.1186 · DOI
  37. Clark, 2006, Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter, Br J Pharmacol, 149, 506, 10.1038/sj.bjp.0706904 · DOI
  38. Kondratov, 2001, Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein, Proc Nat Acad Sci USA, 98, 14078, 10.1073/pnas.241314798 · DOI
  39. Maeno, 2009, Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1), Drug Metab Dispos, 37, 1411, 10.1124/dmd.109.026633 · DOI
  40. El-Sheikh, 2008, Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4), Mol Pharmacol, 74, 964, 10.1124/mol.107.043661 · DOI
  41. Van Aubel, 2005, Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites, Am J Physiol Renal Physiol, 288, F327, 10.1152/ajprenal.00133.2004 · DOI
  42. Chen, 2001, Transport of cyclic nucleotides and estradiol 17-beta-d-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine, J Biol Chem, 276, 33747, 10.1074/jbc.M104833200 · DOI
  43. Sassi, 2008, Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation, J Clin Invest, 118, 2747, 10.1172/JCI35067 · DOI
  44. Yang, 1995, Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations, Cancer Res, 55, 4004
  45. Zhang, 2007, ABCG2/BCRP expression modulates d-Luciferin based bioluminescence imaging, Cancer Res, 67, 9389, 10.1158/0008-5472.CAN-07-0944 · DOI
  46. Chu, 1999, Active efflux of CPT-11 and its metabolites in human KB-derived cell lines, J Pharmacol Exp Ther, 288, 735, 10.1016/S0022-3565(24)38014-0 · DOI
  47. Knasmuller, 1998, Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens, Mutat Res, 402, 185, 10.1016/S0027-5107(97)00297-2 · DOI
  48. Peng, 2009, A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy, PLoS One, 4, e5676, 10.1371/journal.pone.0005676 · DOI
  49. Gudmundsson, 2009, Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1, Bioorg Med Chem Lett, 19, 6399, 10.1016/j.bmcl.2009.09.056 · DOI
  50. Jain, 2005, Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues, Bioorg Med Chem, 13, 4458, 10.1016/j.bmc.2005.04.034 · DOI
  51. Hoque, 2009, Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells, Biochem Biophys Res Commun, 379, 60, 10.1016/j.bbrc.2008.12.014 · DOI

Cited by

Sorted by citations

See all 67

Metadata

Authors
Cheung, L., Flemming, C. L., Watt, F., Masada, N., Yu, D. M. T., Huynh, T., Conseil, G., Tivnan, A., Polinsky, A., Gudkov, A. V., Munoz, M. A., Vishvanath, A., Cooper, D. M. F., Henderson, M. J., Cole, S. P. C., Fletcher, J. I., Haber, M., & Norris, M. D.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2014-09
Volume
91
Issue
1
Pages
97-108
ISSN
0006-2952
DOI
10.1016/j.bcp.2014.05.023
Cited by
67
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review